Similar articles for PMID: 24902520

Year	Number of Results
2004	3
2006	7
2007	3
2008	10
2009	10
2010	8
2011	14
2012	14
2013	11
2014	14
2015	4
2017	2
2020	1
2021	1
2022	3
2024	0

1

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.

Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S, Ristola M, Lundgren JD, Grarup J, Kirk O; EuroSIDA in EuroCOORD. Mocroft A, et al. Infection. 2014 Aug;42(4):757-62. doi: 10.1007/s15010-014-0630-4. Epub 2014 Jun 6. Infection. 2014. PMID: 24902520 Free PMC article.

2

Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.

Deeks ED, Perry CM. Deeks ED, et al. Drugs. 2010 Dec 3;70(17):2315-38. doi: 10.2165/11203800-000000000-00000. Drugs. 2010. PMID: 21080746 Review.

3

Antiretroviral rounds. Is that "one pill" treatment enough?

Gallant JE, Arribas JR. Gallant JE, et al. AIDS Clin Care. 2008 Jul;20(7):53-4. AIDS Clin Care. 2008. PMID: 18724479 No abstract available.

4

First of a kind in HIV treatment.

[No authors listed] [No authors listed] FDA Consum. 2006 Nov-Dec;40(6):34. FDA Consum. 2006. PMID: 17333565 Free article.

5

European Commission approves Atripla.

[No authors listed] [No authors listed] AIDS Patient Care STDS. 2008 Jan;22(1):87-8. AIDS Patient Care STDS. 2008. PMID: 18453042 No abstract available.

6

WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.

Omeje I, Okwundu CI. Omeje I, et al. Cochrane Database Syst Rev. 2012 May 16;2012(5):CD007276. doi: 10.1002/14651858.CD007276.pub3. Cochrane Database Syst Rev. 2012. PMID: 22592718 Free PMC article. Review.

7

WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.

Omeje I, Okwundu CI. Omeje I, et al. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007276. doi: 10.1002/14651858.CD007276.pub2. Cochrane Database Syst Rev. 2012. PMID: 22336829 Updated. Review.

8

No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla.

Burger D, van Luin M, Bosch M, van der Ven A, Brouwer AM, Keuter M, Dofferhoff T, Koopmans PP. Burger D, et al. J Acquir Immune Defic Syndr. 2010 Aug;54(5):e12-3. doi: 10.1097/QAI.0b013e3181ed1896. J Acquir Immune Defic Syndr. 2010. PMID: 20647821 No abstract available.

9

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.

Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, Gallant JE, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J; GS-US-236-0102 Study Team. Zolopa A, et al. J Acquir Immune Defic Syndr. 2013 May 1;63(1):96-100. doi: 10.1097/QAI.0b013e318289545c. J Acquir Immune Defic Syndr. 2013. PMID: 23392460 Clinical Trial.

10

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.

Lyseng-Williamson KA, Scott LJ. Lyseng-Williamson KA, et al. Clin Drug Investig. 2012 Oct 1;32(10):715-22. doi: 10.1007/BF03261925. Clin Drug Investig. 2012. PMID: 22921088

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

99 results

Results by year